Research programme: cancer therapeutics - Imago BioSciences
Latest Information Update: 16 Jan 2023
At a glance
- Originator Imago BioSciences
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 11 Jan 2023 Imago BioSciences has been acquired by Merck & Co
- 28 Jan 2020 No recent reports of development identified for research development in Cancer in USA